Yes, this is a class of thing that is obviously being studied. Check out tesamorelin etc. but there is also a Phase 1 somewhere for BPC-157.

The peptides themselves are being used for everything but realistically, considering the costs, you have to innovate a little. Here’s a little example with GLP-1: the core biology and mechanism were well understood. But use was like the grey market peptides you were talking about: a daily injection. Half life is super short because DPP4 chews through.

So you need some innovation first to make it last so that you can bring it to market. Perhaps they misread the market and didn’t realize that for sufficient weight loss people would inject daily. But anyway, the liraglutide, dulaglutide, semaglutide, are various attempts at this to preserve function while raising half life in the body.

If you want to accelerate this research you’re really going to have to reform the whole process of medical testing and this and that but most things are not so dangerous that you need to rush to release a drug. Not everything is COVID-19 or obesity. Getting a PDA trial so some few people can heal faster from workout injuries is probably going to be a hard sell, even on this forum.

I’m of the view that the combination of grey market and clean market supply is a great way to serve latent desire as well as safe mass access.

One funny thing that a researcher told me (on seeing my lab notebook of my retatrutide self tests) is that it complicates baseline wide population studies. The total population is also losing weight, not just known GLP-1RA users. It turns out grandpa and grandma are reconstituting vials with BAC in New Salem, Oklahoma.

It seems like pharma developed many of them, but it takes a while to get them to market.